AstraZeneca plc (NYSE:AZN) – Investment analysts at Jefferies Group lowered their FY2018 earnings estimates for shares of AstraZeneca in a note issued to investors on Tuesday. Jefferies Group analyst J. Holford now forecasts that the company will post earnings per share of $1.78 for the year, down from their previous estimate of $1.94. Jefferies Group also issued estimates for AstraZeneca’s FY2019 earnings at $1.88 EPS, FY2020 earnings at $2.19 EPS, FY2021 earnings at $2.68 EPS and FY2022 earnings at $3.21 EPS.
AZN has been the topic of a number of other reports. JPMorgan Chase & Co. upgraded shares of AstraZeneca from a “neutral” rating to an “overweight” rating in a research note on Friday, December 29th. Leerink Swann increased their price objective on shares of AstraZeneca from $31.00 to $34.00 and gave the company a “market perform” rating in a research note on Monday, October 23rd. Zacks Investment Research downgraded shares of AstraZeneca from a “hold” rating to a “sell” rating in a research note on Wednesday, January 3rd. Credit Suisse Group upgraded shares of AstraZeneca from a “neutral” rating to an “outperform” rating in a research note on Monday, October 16th. Finally, BMO Capital Markets set a $38.00 price objective on shares of AstraZeneca and gave the company a “buy” rating in a research note on Wednesday, November 15th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and thirteen have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $34.48.
AstraZeneca (NYSE:AZN) last issued its earnings results on Thursday, November 9th. The company reported $1.12 EPS for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. The business had revenue of $6.23 billion for the quarter, compared to analyst estimates of $6 billion. AstraZeneca had a net margin of 15.90% and a return on equity of 34.02%. The company’s quarterly revenue was up 9.4% compared to the same quarter last year. During the same period last year, the company posted $1.32 earnings per share.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Fisher Asset Management LLC boosted its stake in AstraZeneca by 4.7% in the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after acquiring an additional 519,717 shares in the last quarter. Wells Fargo & Company MN boosted its stake in AstraZeneca by 7.6% in the third quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock valued at $149,303,000 after acquiring an additional 310,389 shares in the last quarter. Ameriprise Financial Inc. lifted its stake in shares of AstraZeneca by 7.1% during the third quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock worth $102,643,000 after buying an additional 199,519 shares during the period. Capital Bank & Trust Co lifted its stake in shares of AstraZeneca by 2.1% during the third quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock worth $92,499,000 after buying an additional 57,353 shares during the period. Finally, Dimensional Fund Advisors LP lifted its stake in shares of AstraZeneca by 18.3% during the third quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock worth $86,695,000 after buying an additional 395,699 shares during the period. Institutional investors own 14.75% of the company’s stock.
WARNING: This story was originally published by Week Herald and is owned by of Week Herald. If you are accessing this story on another website, it was stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this story can be viewed at https://weekherald.com/2018/01/18/fy2018-earnings-estimate-for-astrazeneca-plc-azn-issued-by-jefferies-group.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.